CooperVision
CooperVision is a global vision-care company specializing in soft, specialty, and myopia-management contact lenses.
Last updated October 14, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
CooperVision is a global vision-care business specializing in contact lenses and related information for lens wearers and eye-care professionals. It operates as the contact-lens division of The Cooper Companies and presents a portfolio intended to address common and specialized vision-correction needs, including daily-wear, monthly-wear, astigmatism and presbyopia applications. Its named product families include Biofinity, MyDay and Proclear. The brand’s public-facing role combines product development and manufacturing with education about contact-lens use. Its website provides product information and guidance for people considering or already wearing contact lenses, while also supporting the professional channel through which lenses are prescribed, fitted and supplied. This makes CooperVision primarily a healthcare and medical-device brand rather than a general consumer packaged-goods label. CooperVision’s portfolio is structured around different wearing schedules and optical requirements. Daily disposable products are designed for single-day use, while reusable products are intended for replacement on a prescribed schedule. Other lines are positioned for wearers whose needs include astigmatism correction or multifocal vision correction. The Biofinity, MyDay and Proclear families serve as recognizable examples of the brand’s product architecture, although the availability of individual products and variants can differ by market and regulatory status. The company describes itself as serving contact-lens wearers worldwide. Its international presence is therefore reflected not only in distribution, but also in the need to adapt product availability, professional guidance and regulatory communications to individual markets. The official website is the principal reference for its current product information and consumer education. Available reference material does not establish a reliable founding year, named founder, detailed executive history, or a complete chronology of acquisitions and product launches. Those fields are consequently left unfilled rather than inferred. The brand is currently active and remains part of The Cooper Companies’ broader vision-care portfolio.
History
CooperVision is the contact-lens operating division of The Cooper Companies. Its business is centered on the development, manufacture and distribution of contact lenses for a broad range of vision-correction requirements. Public-facing materials describe the brand as serving contact-lens wearers worldwide and provide product information together with guidance related to contact-lens use. The brand’s portfolio is organized around practical and clinical differences among wearers. It includes products for daily disposable use and reusable replacement schedules, as well as lenses designed for astigmatism and multifocal vision correction. Biofinity, MyDay and Proclear are among the product families associated with CooperVision. These families illustrate the brand’s focus on combining replacement convenience with optical designs intended for different prescriptions and wearing needs. CooperVision’s market role extends beyond direct consumer recognition. Contact lenses are generally selected, fitted and supplied through eye-care professionals, so the business must support both wearers and the professional ecosystem. Its official website functions as a source of product information and contact-lens advice, while market-specific operations may vary according to local regulation, product authorization and distribution arrangements. The available reference material does not provide a verified founding date, founder, detailed corporate chronology, named executives, financial history or a documented list of major campaigns and controversies. Those details are not included here. Based on the supplied materials, CooperVision is an active global brand within The Cooper Companies, focused on contact lenses and related vision-care information.
- 2024
Fourth consecutive MiSight consumer campaign launched
[6]CooperVision launched “MiSight Today. Anything Tomorrow.” to increase parent awareness of childhood myopia and encourage eye examinations and professional consultation.
- 2023
SynergEyes acquisition completed
[10]The SynergEyes acquisition was completed, adding hybrid and specialty scleral-lens products and expertise.
- 2022
EnsEyes acquired
[8]The company acquired Danish specialty-lens manufacturer EnsEyes to support growth in the Nordic region.
- 2022
SynergEyes acquisition announced
[9]CooperVision announced an agreement to acquire SynergEyes and expand its North American specialty-lens portfolio.
- 2020
GP Specialists added to specialty portfolio
[5]CooperVision acquired GP Specialists, expanding its rigid gas-permeable and custom specialty-lens capabilities.
- 2019
Blanchard Contact Lenses acquired
[5]CooperVision added Blanchard’s specialty and scleral-lens expertise to its portfolio.
- 2019
MiSight 1 day receives FDA approval
[7]MiSight 1 day became the first soft contact lens approved by the FDA to slow myopia progression in appropriately selected children aged 8–12 at treatment initiation.
- 2017
Paragon Vision Sciences acquired
[5]The acquisition expanded CooperVision’s orthokeratology and specialty-eye-care capabilities.
- 2014
Sauflon acquisition completed
[12]CooperVision completed the acquisition of Sauflon Pharmaceuticals, strengthening its daily disposable and silicone-hydrogel product capabilities.
- 2012
Rebrand recognized by REBRAND 100
[5]The CooperVision rebranding was recognized among the REBRAND 100 global award recipients.
Products and positioning
A global medical-device and vision-care brand positioned around broad prescription coverage, advanced soft-lens materials and optics, specialty contact lenses, myopia management, and practitioner partnership. CooperVision serves both everyday contact-lens wearers and patients with more complex needs through eye-care professionals and authorized distribution channels.
Reusable silicone-hydrogel contact lenses
Biofinity
Biofinity is one of CooperVision’s core reusable silicone-hydrogel families. The range includes spherical lenses for routine prescriptions, Biofinity XR for expanded parameters, toric lenses for astigmatism, multifocal lenses for presbyopia, and toric multifocal designs. Related Biofinity Energys products are positioned for wearers who spend substantial time using digital devices. The family is a central part of CooperVision’s monthly replacement portfolio and is distributed through eye-care professionals and authorized channels.
Daily disposable silicone-hydrogel contact lenses
MyDay
MyDay is CooperVision’s major daily disposable silicone-hydrogel platform. It includes spherical daily lenses, MyDay toric for astigmatism, MyDay multifocal for presbyopia, and MyDay Energys for digital-lifestyle positioning. The family emphasizes single-use convenience, oxygen transmission, broad prescription coverage, and everyday comfort. It is marketed as part of CooperVision’s premium daily-disposable portfolio and is available in multiple international markets.
Daily disposable silicone-hydrogel contact lenses
clariti 1 day
clariti 1 day is a daily disposable silicone-hydrogel family designed to provide a broad alternative for routine vision correction. The family includes spherical, toric, and multifocal products. CooperVision positions clariti 1 day around daily replacement, silicone-hydrogel material benefits, and access to a wide range of prescriptions. Availability and exact parameters vary by market.
Myopia-management daily disposable contact lens · 2019
MiSight 1 day
MiSight 1 day is a single-use soft contact lens designed to correct myopic ametropia and slow myopia progression in children who meet the applicable regulatory indication. Its ActivControl optical design combines vision-correction zones with treatment zones intended to create myopic defocus. The product received U.S. FDA approval in 2019 for appropriately selected children aged 8–12 at treatment initiation. CooperVision supports the product with practitioner certification, clinical education, parent resources, and consumer-awareness campaigns.
Reusable silicone-hydrogel contact lenses
Avaira Vitality
Avaira Vitality is a reusable silicone-hydrogel lens family that includes spherical and toric designs. It forms part of CooperVision’s monthly or reusable soft-lens portfolio and is intended for wearers seeking a balance of replacement convenience, oxygen transmission, and silicone-hydrogel material performance. The brand has also been associated with the company’s 2011–2012 recall involving selected Avaira lots.
Orthokeratology contact lenses
Paragon CRT
Paragon CRT is an orthokeratology lens platform associated with CooperVision’s specialty-eye-care business following the acquisition of Paragon Vision Sciences. Orthokeratology lenses are designed for overnight wear under professional supervision to temporarily reshape the cornea and provide daytime vision correction. The portfolio is supported by specialty fitting, practitioner education, and diagnostic expertise.
Scleral contact lenses
Blanchard Onefit
Blanchard Onefit is a specialty scleral-lens platform associated with CooperVision Specialty EyeCare. Scleral lenses vault the cornea and rest on the sclera, making them useful for selected patients with irregular corneas, ocular-surface disease, or other complex fitting needs. The product family reflects CooperVision’s strategy of combining mainstream soft lenses with advanced custom and specialty designs.
Hybrid and specialty contact lenses
SynergEyes hybrid and scleral lenses
SynergEyes products broaden CooperVision’s specialty portfolio through hybrid and scleral designs. Hybrid lenses combine a rigid center with a soft peripheral skirt, while scleral lenses vault the cornea and are used for selected irregular-cornea and ocular-surface indications. CooperVision completed its acquisition of SynergEyes in 2023 and has incorporated the business into its North American specialty-eye-care activities.
Controversies
2011
Avaira contact-lens recall
CooperVision recalled certain Avaira toric contact-lens lots in August 2011 after complaints of hazy vision and an investigation identified silicone-oil residue in affected lots. The recall was later expanded to include certain spherical Avaira lenses. The event was a product-quality and regulatory issue rather than evidence of intentional misconduct.
Marketing campaigns
- 2024MiSight Today. Anything Tomorrow.
United States
CooperVision’s fourth consecutive consumer-facing myopia campaign used digital, audio, video, social, and content partnerships to encourage parents to act on children’s myopia and arrange comprehensive eye examinations.
Outcome. CooperVision reported that its preceding four-year consumer-awareness efforts generated more than one billion impressions and more than 71 million actions, based on company campaign data.
- 2023MiSight 1 day back-to-school campaign
United States
The campaign targeted parents and caregivers before the school year, encouraging comprehensive eye examinations and conversations with eye-care professionals about myopia management.
Outcome. The campaign directed families to MiSight educational resources and certified practitioners and extended CooperVision’s parent-focused myopia-awareness work.
- 2021Make Children’s Sight Your Fight
United States
CooperVision developed a professional and consumer education platform around childhood myopia, encouraging early discussion of progression and available management options.
Outcome. The initiative helped build the practitioner and parent education infrastructure later used in the company’s recurring MiSight consumer campaigns.
- 2018CooperVision practitioner and academic education programs
United States · North America
CooperVision used educator meetings, resident programs, professional affairs activities, and specialty-lens training to support optometry students, educators, and practitioners.
Outcome. The programs promoted specialty-lens knowledge, practitioner development, charitable grants, and greater familiarity with CooperVision’s specialty portfolio.
- 2011CooperVision global rebrand
Global
CooperVision introduced a global corporate identity developed with Siegel+Gale to create a more consistent expression across its international contact-lens business.
Outcome. The rebrand was subsequently recognized among the 2012 REBRAND 100 global award recipients.
Brand decisions
2024
Continue direct-to-consumer myopia awareness investmentStrategyBackground
CooperVision identified parent awareness and early professional consultation as important to increasing adoption of myopia-management care.
Action taken
The company launched its fourth consecutive consumer-facing campaign, “MiSight Today. Anything Tomorrow.”, with digital, audio, video, social, and content-partnership components.
Aftermath
The campaign reinforced CooperVision’s position in pediatric myopia management and directed families toward eye examinations, certified practitioners, and MiSight resources.
2022
Acquire EnsEyesM&ABackground
CooperVision aimed to accelerate specialty contact-lens growth in the Nordic region and add regional fitting and distribution expertise.
Action taken
CooperVision acquired EnsEyes, a Danish specialty contact-lens manufacturer.
Aftermath
The transaction expanded the company’s European specialty-eye-care presence.
2022
Acquire SynergEyesM&ABackground
CooperVision sought to increase specialty-lens adoption in North America and broaden its hybrid and scleral product offering.
Action taken
The company announced the acquisition of SynergEyes in November 2022 and completed it in January 2023.
Aftermath
SynergEyes expanded CooperVision’s specialty portfolio and added hybrid and scleral-lens expertise.
2019
Obtain FDA approval for MiSight 1 dayProduct launchBackground
CooperVision pursued a regulated myopia-management product supported by randomized clinical research into dual-focus contact lenses and axial eye growth.
Action taken
The company obtained FDA approval for MiSight 1 day for correction of myopic ametropia and slowing myopia progression in appropriately selected children aged 8–12 at treatment initiation.
Aftermath
MiSight became the centerpiece of CooperVision’s myopia-management strategy, supported by practitioner certification, parent education, and recurring consumer campaigns.
2017
Expand into orthokeratology through Paragon Vision SciencesM&ABackground
CooperVision identified specialty eye care as a way to complement its high-volume soft-lens business and address more complex vision needs.
Action taken
The company completed the acquisition of Paragon Vision Sciences and incorporated its orthokeratology capabilities into the specialty portfolio.
Aftermath
The acquisition strengthened CooperVision’s position in overnight corneal reshaping and specialty practitioner education.
2014
Acquire Sauflon PharmaceuticalsM&ABackground
CooperVision wanted to strengthen its daily-disposable and silicone-hydrogel offering and expand its international operating footprint.
Action taken
CooperVision completed the acquisition of United Kingdom-based Sauflon Pharmaceuticals in August 2014.
Aftermath
Sauflon’s manufacturing and product capabilities supported CooperVision’s broader daily-disposable portfolio.
2004
Acquire Ocular SciencesM&ABackground
CooperVision sought to increase its scale in soft contact lenses and strengthen its global manufacturing and marketing position.
Action taken
The company announced the acquisition of Ocular Sciences in 2004 and completed the transaction on January 7, 2005.
Aftermath
The transaction substantially expanded CooperVision’s soft-lens business and helped make it one of the world’s largest soft-contact-lens manufacturers.
Recent events
Reported
CooperVision partners with eye-care organizations on myopia[15]
CooperVision announced partnerships with the American Academy of Ophthalmology and the World Council of Optometry to address worldwide myopia and promote a standard of care. The initiatives include global resources such as multilingual myopia-management resources and programming.
Sources15 sources
- 1About CooperVisioncoopervision.com
- 2CooperVision Global Leadershipcoopervision.com
- 3CooperVision U.S. Leadershipcoopervision.com
- 4CooperVision: Our Storied Historycoopervision.com
- 5CooperVisionen.wikipedia.org
- 6CooperVision launches fourth consecutive direct-to-consumer campaigncoopervision.com
- 7CooperVision announces approval of MiSight 1 daycoopervision.com
- 8CooperVision acquires EnsEyescoopervision.com
- 9CooperVision adds SynergEyesprnewswire.com
- 10CooperVision completes acquisition of SynergEyesclm.com
- 11CooperVision product reference guidecoopervision.com
- 12Sauflon acquisition completedcoopervision.com
- 13Make Children’s Sight Your Fightcoopervision.com
- 14CooperVision practitioner and academic education programscoopervision.com
- 15CooperVision 与眼科组织合作应对近视healio.com
Cite this profile: Cite the canonical profile. /brand-wiki/coopervision · Editorial policy · How profiles are compiled